{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:59:28Z","timestamp":1776855568190,"version":"3.51.2"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.acvd.2021.12.003","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T13:10:56Z","timestamp":1643721056000},"page":"78-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["One-year care pathway after acute myocardial infarction in 2018: Prescription, medical care and medication adherence, using a French health insurance reimbursement database"],"prefix":"10.1016","volume":"115","author":[{"given":"Karin","family":"Martin-Latry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Latry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Berges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Coste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Douard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Pucheu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Couffinhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2021.12.003_bib0205","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/eurheartj\/ehq326","article-title":"Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study)","volume":"31","author":"Fox","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.12.003_bib0210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.12.003_bib0215","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijcard.2014.09.023","article-title":"Determinants of improved one-year survival in non-ST-segment elevation myocardial infarction patients: insights from the French FAST-MI program over 15 years","volume":"177","author":"Puymirat","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2021.12.003_bib0220","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.107.706820","article-title":"Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction","volume":"117","author":"Jackevicius","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.12.003_bib0225","first-page":"1413","article-title":"Dual antiplatelet therapy after myocardial infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database","volume":"7","author":"Latry","year":"2012","journal-title":"Euro Interv"},{"key":"10.1016\/j.acvd.2021.12.003_bib0230","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2261-11-46","article-title":"Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study","volume":"11","author":"Latry","year":"2011","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.acvd.2021.12.003_bib0235","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.acvd.2010.05.003","article-title":"Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization","volume":"103","author":"Tuppin","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2021.12.003_bib0240","series-title":"Adherence to long-term therapies: evidence for action","author":"Sabate","year":"2003"},{"key":"10.1016\/j.acvd.2021.12.003_bib0245","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/pds.4171","article-title":"Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.acvd.2021.12.003_bib0250","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/pds.3840","article-title":"Effect of adherence to evidence-based therapy after acute myocardial infarction on all-cause mortality","volume":"24","author":"Hamood","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.acvd.2021.12.003_bib0255","doi-asserted-by":"crossref","first-page":"e004356","DOI":"10.1161\/CIRCOUTCOMES.117.004356","article-title":"Clinical events after discontinuation of beta-blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French healthcare databases","volume":"11","author":"Neumann","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.acvd.2021.12.003_bib0260","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1177\/2047487318808638","article-title":"Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: the FAST-MI 2010 registry","volume":"26","author":"Tea","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.acvd.2021.12.003_bib0265","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00228-013-1614-5","article-title":"Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France","volume":"70","author":"Bezin","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.acvd.2021.12.003_bib0270","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ijcard.2016.06.102","article-title":"Outcomes following acute hospitalised myocardial infarction in France: an insurance claims database analysis","volume":"219","author":"Blin","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2021.12.003_bib0275","unstructured":"Vivre apr\u00e8s un infarctus du myocarde. Available at: https:\/\/www.ameli.fr\/assure\/sante\/themes\/infarctus-myocarde\/vivre-infarctus.[accessed date: 11 August 2021]."},{"key":"10.1016\/j.acvd.2021.12.003_bib0280","unstructured":"Haute Autorit\u00e9 de sant\u00e9 (HAS). Programme infarctus 2007-2010. Available at: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2009-04\/etape3_vf.pdf.[accessed date: 11th August 2021]."},{"key":"10.1016\/j.acvd.2021.12.003_bib0285","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00008483-200401000-00008","article-title":"Specific profile and referral bias of rehabilitated patients after an acute coronary syndrome","volume":"24","author":"Cottin","year":"2004","journal-title":"J Cardiopulm Rehabil"},{"key":"10.1016\/j.acvd.2021.12.003_bib0290","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.acvd.2017.07.003","article-title":"National trends in admission for cardiac rehabilitation after a myocardial infarction in France from 2010 to 2014","volume":"111","author":"Gabet","year":"2018","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2021.12.003_bib0295","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.acvd.2015.09.009","article-title":"Cardiac rehabilitation and 5-year mortality after acute coronary syndromes: the 2005 French FAST-MI study","volume":"109","author":"Pouche","year":"2016","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2021.12.003_bib0300","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/eurheartj\/ehi705","article-title":"Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction","volume":"27","author":"Gislason","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.12.003_bib0305","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/archinte.166.17.1842","article-title":"Impact of medication therapy discontinuation on mortality after myocardial infarction","volume":"166","author":"Ho","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.acvd.2021.12.003_bib0310","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.acvd.2009.02.005","article-title":"Combined secondary prevention after hospitalization for myocardial infarction in France: analysis from a large administrative database","volume":"102","author":"Tuppin","year":"2009","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2021.12.003_bib0315","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/pds.1912","article-title":"Pharmacoepidemiological research using French reimbursement databases: yes we can!","volume":"19","author":"Martin-Latry","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.acvd.2021.12.003_bib0320","unstructured":"Agence technique de l\u2019information sur l\u2019hospitalisation (ATIH). Classification internationale des maladies (CIM). Available at: https:\/\/www.atih.sante.fr\/nomenclatures-de-recueil-de-linformation\/cim.[accessed date: 23 March 2021]."},{"key":"10.1016\/j.acvd.2021.12.003_bib0325","first-page":"S87","article-title":"Cha\u00eenage des donn\u00e9es du PMSI avec les donn\u00e9es de remboursement de l\u2019assurance-maladie: exemple de l\u2019analyse de la pr\u00e9vention secondaire apr\u00e8s un infarctus du myocarde","volume":"57","author":"Tuppin","year":"2009","journal-title":"Respe"},{"key":"10.1016\/j.acvd.2021.12.003_bib0330","unstructured":"Club Inter Pharmaceutique (CIP). Nos services. Available at: https:\/\/www.cipmedicament.org\/nos-services\/.[accessed date: 23 March 2021]."},{"key":"10.1016\/j.acvd.2021.12.003_bib0335","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.jhh.1001873","article-title":"Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study","volume":"19","author":"Bourgault","year":"2005","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.acvd.2021.12.003_bib0340","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.clinthera.2006.09.021","article-title":"Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization","volume":"28","author":"Caetano","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.acvd.2021.12.003_bib0345","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.mlr.0000207817.32496.cb","article-title":"Validity of a prescription claims database to estimate medication adherence in older persons","volume":"44","author":"Grymonpre","year":"2006","journal-title":"Med Care"},{"key":"10.1016\/j.acvd.2021.12.003_bib0350","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1345\/aph.1H018","article-title":"Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures","volume":"40","author":"Hess","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.acvd.2021.12.003_bib0355","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/00005650-198808000-00007","article-title":"A general method of compliance assessment using centralized pharmacy records. Description and validation","volume":"26","author":"Steiner","year":"1988","journal-title":"Med Care"},{"key":"10.1016\/j.acvd.2021.12.003_bib0360","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0895-4356(96)00268-5","article-title":"The assessment of refill compliance using pharmacy records: methods, validity, and applications","volume":"50","author":"Steiner","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.acvd.2021.12.003_bib0365","doi-asserted-by":"crossref","first-page":"e0202986","DOI":"10.1371\/journal.pone.0202986","article-title":"Patients\u2019 adherence to optimal therapeutic, lifestyle and risk factors recommendations after myocardial infarction: six years follow-up in primary care","volume":"13","author":"Dibao-Dina","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.acvd.2021.12.003_bib0370","doi-asserted-by":"crossref","first-page":"e011765","DOI":"10.1161\/JAHA.118.011765","article-title":"Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry","volume":"8","author":"Bradley","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2021.12.003_bib0375","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1177\/2047487318781359","article-title":"Determinants of participation and risk factor control according to attendance in cardiac rehabilitation programmes in coronary patients in Europe: EUROASPIRE IV survey","volume":"25","author":"Kotseva","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.acvd.2021.12.003_bib0380","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10557-020-07095-6","article-title":"Medical treatment in coronary patients: is there still a gender gap? Results from European Society of Cardiology EUROASPIRE V registry","volume":"35","author":"Vynckier","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.acvd.2021.12.003_bib0385","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.acvd.2019.04.002","article-title":"Outcome associated with prescription of cardiac rehabilitation according to predicted risk after acute myocardial infarction: insights from the FAST-MI registries","volume":"112","author":"Puymirat","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2021.12.003_bib0390","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.acvd.2021.12.003_bib0395","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1001\/jama.1993.03500210079036","article-title":"The rational clinical examination. Is this patient taking the treatment as prescribed?","volume":"269","author":"Stephenson","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2021.12.003_bib0400","unstructured":"D\u00e9finition de l\u2019ALD. Available at: https:\/\/www.ameli.fr\/medecin\/exercice-liberal\/presciption-prise-charge\/situation-patient-ald-affection-longue-duree\/definition-ald.[accessed date: 9th June 2021]."}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213622000134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213622000134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:47:32Z","timestamp":1761745652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213622000134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1875213622000134"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2021.12.003","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One-year care pathway after acute myocardial infarction in 2018: Prescription, medical care and medication adherence, using a French health insurance reimbursement database","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2021.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}